Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Policy / Regulatory

Sichuan Healthcare Security Administration Announces VBP for Oral Implant Systems

Fineline Cube Dec 27, 2022

The Sichuan Provincial Healthcare Security Administration has released a notification regarding the inter-provincial alliance volume-based...

Company Drug

Junshi Biosciences’ PD-1 Inhibitor Tuoyi Faces FDA Review Delay

Fineline Cube Dec 27, 2022

Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that they have not received...

Company Drug

Huadong Medicine’s Lanluma V and X Approved for Use in Hainan

Fineline Cube Dec 27, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving approval from the Hainan Medical...

Company Drug

Antengene and MSD Collaborate on Global Clinical Study for ATG-037

Fineline Cube Dec 27, 2022

China-based Antengene Corporation Limited (HKG: 6996) has announced a global clinical collaboration with Merck, Sharp...

Company Drug

IASO Biotherapeutics Receives FDA Approval for CT103A IND Application

Fineline Cube Dec 27, 2022

China-based IASO Biotherapeutics has announced approval from the US FDA for an Investigational New Drug...

Company Deals

Shenzhen Würzburg Dynamics Raises RMB 100 Million in Series A Financing Round

Fineline Cube Dec 27, 2022

China-based Shenzhen Würzburg Dynamics has reportedly raised RMB 100 million (USD 14.36 million) in a...

Company Deals

AcornMed Raises RMB 200 Million in Series B Financing Led by Yikai Venture Capital

Fineline Cube Dec 27, 2022

AcornMed, a tumor precision medicine specialist based in Beijing, has reportedly raised RMB 200 million...

Company Drug

CSPC’s NBL-020 Receives FDA IND Approval for Advanced Solid Tumors

Fineline Cube Dec 26, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving Investigational New Drug (IND) approval...

Company Drug

Jiangsu Chia Tai Tianqing’s TQB2102m Gains NMPA Clinical Approval

Fineline Cube Dec 26, 2022

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd’s (CTTQ) Category 1 biologic product TQB2102m, an HER2...

Company Deals

WuXi XDC Partners with GeneQuantum for ADC Development

Fineline Cube Dec 26, 2022

China-based WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a...

Company Drug

Hengrui Pharmaceuticals Receives New Approval for Remimazolam Tosylate

Fineline Cube Dec 26, 2022

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced one new supplementary approval for its gamma-aminobutyric...

Company Deals

Neurophth Partners with Apellis for Gene Therapy Development in AMD

Fineline Cube Dec 26, 2022

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with US firm...

Company Drug

Jing Medicine’s HJM-353 Gains Clinical Trial Approvals in US and China

Fineline Cube Dec 26, 2022

China-based Jing Medicine Technology (Shanghai) Co., Ltd’s HJM-353 has obtained clinical trial approvals in the...

Company Deals

Jiangsu Vcare PharmaTech Raises RMB 200 Million in Series B Financing Round

Fineline Cube Dec 26, 2022

China-based Jiangsu Vcare PharmaTech Co. Ltd has reportedly raised over RMB 200 million (USD 28.67...

Company Drug

MindRank AI Receives FDA Approval for MDR-001 Clinical Study in Obesity

Fineline Cube Dec 26, 2022

Hangzhou-based artificial intelligence (AI)-driven biotech MindRank AI has announced obtaining approval from the US FDA...

Company Medical Device

Hangzhou Biotest Receives FDA EUA for COVID-19 Antigen Self-Testing Reagent

Fineline Cube Dec 26, 2022

China-based Hangzhou Biotest Biotech Co., Ltd has announced receiving an Emergency Use Authorization (EUA) from...

Company Deals

Junshi Biosciences Licenses PD-1 Inhibitor Tuoyi to Hikma MENA FZE

Fineline Cube Dec 26, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a licensing agreement with UK-headquartered Hikma...

Company Deals

Shanghai Pharmaceuticals Secures Exclusive Rights for Shionogi’s Ensitrelvir in China

Fineline Cube Dec 26, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has announced an import and distribution agreement with Japan-based...

Company Drug

WHO Approves Sinovac’s CoronaVac for Children Aged 3 and Above

Fineline Cube Dec 23, 2022

The World Health Organization (WHO) has lowered the age limit for Sinovac Biotech Ltd’s (NASDAQ:...

Policy / Regulatory

NHSA Orders Investigation into Unreasonable Medical Insurance Restrictions

Fineline Cube Dec 23, 2022

The National Healthcare Security Administration (NHSA) has released a notification to medical insurance departments across...

Posts pagination

1 … 606 607 608 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.